Table 3.
Clinical Responses in All Patients and in Patients with or without Previous BCMA-Directed Therapies.
| Response | All Patients | Previous BCMA Therapies | No Previous BCMA Therapies | |||
|---|---|---|---|---|---|---|
| All Dose Levels (N = 17) | 25×106–150×106 CAR T Cells (N = 12) | All Dose Levels (N = 10) | 25×106–150×106 CAR T Cells (N = 6) | All Dose Levels (N = 7) | 25×106–150×106 CAR T Cells (N = 6) | |
| number (percent) | ||||||
| Partial response or better | 12 (71) | 7 (58) | 7 (70) | 3 (50) | 5 (71) | 4 (67) |
| Very good partial response or better | 10 (59) | 5 (42) | 6 (60) | 2 (33) | 4 (57) | 3 (50) |
| Complete response or better | 6 (35) | 3 (25) | 4 (40) | 2 (33) | 2 (29) | 1 (17) |
| Negativity for MRD in bone marrow* | 8 (47) | 6 (50) | 3 (30) | 2 (33) | 5 (71) | 4 (67) |
*
Negativity for minimal residual disease (MRD) in bone marrow was assessed by means of 10-color flow cytometry with a sensitivity of 1 in 105 at 4 weeks after CAR T-cell therapy, at the occurrence of a complete response, and as clinically indicated.